e-Poster Presentations 1379 Abstracts
Choice of Abstracts with PEGASPARGASE
Maria Moreno, Amanda Wolfe, Celina Dara, et al.
The authors conclude:
Based on TDM, optimal dosing of q21day Pegaspargase was defined. The results of a prospective validation of this dosing regimen, as well as an analysis of the cost savings resulting from lower Pegaspargase doses, will be presented.
————————————————————————————————————————————————————————
The authors conclude:
ASP containing regimens are associated with excellent CR rates and survival outcomes in older adult ALL patients. However, severe ARTs are frequent, most commonly in the form of hepatotoxicity and generally lead to treatment-delays, asparaginase dose reduction or premature cessation. While ASP improves outcomes in older ALL patients, pre-emptive ASP dose reduction in older adults may improve its tolerability and deliverability.
————————————————————————————————————————————————————————
The authors conclude:
Asparaginase associated pancreatitis remains to be a significant cause of mortality and morbidity in children with ALL.
————————————————————————————————————————————————————————
PB1800 SEIZURE AS A RARE SIDE EFFECT OF L-ASPARAGINASE INFUSION IN A LEUKEMIC CHILD WITH DOWN SYNDROME
The authors conclude:
Seizure during chemotherapy infusion in the literature has been shown very rarely. With this case, we have shown that seizure may develop besides the most common anaphylaxis side effect during l-asparaginase infusion.